Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by spammeon Aug 19, 2010 9:37pm

363 Views

Post# 17367662

RE: RE: Haywood target 2.40

I wouldn't trust Haywood. They are the underwriters for BRD so of course they are going to say nice things.
They cover another company that I invested in (unforunately) and were very bullish on it GBS Gold. It went bankrupt during the meltdown of 2008. I am not saying BRD does not have potential because I think it does.
But of course there are risks too (e.g. can they meet their targets ounces?)
But trusting some seedy 2 bit investment house's target price is useless.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!